MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ability and quality of life in a small midphase trial. A total of 14 ...
Gene therapy specialist Meiragtx Holdings plc got a market bump courtesy of newly released top-line data from its phase II bridging study in Parkinson’s disease. The six-month, three-arm randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback